Business
Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
Encinitas, California--(Newsfile Corp. - March 30, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced its late-breaking
About this update from Kiora Pharmaceuticals, Inc.
[{"type":"text","content":"Encinitas, California--(Newsfile Corp. - March 30, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (\"Kiora\" or the \"Company\") announced its late-breaking abstract detailing functional Magnetic Resonance Imaging (fMRI) results from the ABACUS Phase 1b study of KIO-301 in patients with retinitis pigmentosa was accepted for presentation on May 1, 2023, at The American Society of Neuroradiology 2023 (ASNR23) Annual Meeting.\nChristen Barras, MBBS, Ph.D., Neuroradiologist at Jones Radiology, Associate Professor of Radiology at the University of Adelaide, in Adelaide, Australia, and an investigator in the ABACUS study, will present fMRI results for initial patients treated with KIO-301, a novel light-sensing small-molecule (\"photoswitch\") intended to restore sight in patients with the orphan disease retinitis pigmentosa. fMRI is a non-invasive imaging technique being used to assess visual cortex activity in response to specific light stimuli.\n\"One of the aims of the ABACUS study is to investigate whether KIO-301 reignites the retina, and to see if that reanimation reaches the level of the brain. These fMRI data help us understand whether that cortical reconnection is occurring,\" said Dr. Barras. ABACUS is the first-in-man clinical trial evaluating photoswitches in patients with no or ultra-low vision.\nPresentation details:\n\nTitle: \"Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal 'Photoswitch' Molecule (KIO-301): Functional MRI Protocol and Preliminary In-Human Observations.\"\nPresenter: Christen Barras, MBBS, Ph.D.\nDate and time: May 1, 2023, 5:26 PM CDT\n\nAbout Kiora Pharmaceuticals\nKiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (\"OPRA\"). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (\"DHODH\") with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell pro...